Industry News
AGT Biosciences chases new market
Buoyed by the data from a recent research paper out of Cambridge University, gene discovery biotech AGT Biosciences has announced it has broadened its patent covering PARL (formerly gene AGT203) to cover cancer, aging and some other diseases. [ + ]
Novogen scores new US patent
Biopharma Novogen has been granted a US patent for isoflavone treatment for fibroids and endometriosis specific to women. [ + ]
APAF ups the discovery ante
The Australian Proteome Analysis Facility (APAF) has "dramatically increased its throughput capability" with the installation of a new Applied Biosystems 4700 Proteomics Discovery System. [ + ]
Victor Chang Institute to work with BioDiem
Sydney's Victor Chang Cardiac Research Institute has signed a deal to investigate a tissue restorative agent, BDM-K, for Melbourne biopharma BioDiem [ + ]
EpiTan answers ASX trading query
Melbourne-based EpiTan's share price (ASX:EPT) has doubled since April, but that's just because of increased market awareness, the company has told the Australian Stock Exchange. [ + ]
New fund aims to raise $150m for Australian biotech
A new fund, spearheaded by stockbrokers Intersuisse, British VC Rothschild Bioscience Managers and Sequence Capital Group, aims to raise AUD$150 million and overseas backing for Australian biotech companies. [ + ]
Global role for atmospheric scientist
An Australian scientist has been elected Vice-President of the international body that guides research into the nature of our planet.
[ + ]UK researcher's eyes opened by biotech activity down under
UK scientist and entrepreneur Prof Peter Shepherd is amazed at how much biotechnology activity there is in Australia. [ + ]
AVI seeks orphan status for experimental SARS drug
US firm Avi BioPharma has asked US regulators to grant 'orphan' status to its experimental drug against the virus that causes SARS, a designation meant to provide seven years of marketing exclusivity for medicines. [ + ]
Watch for new wave of mad cow: Masters
While the incidence of variant Creutzfeldt-Jakob disease (vCJD) -- the human form of mad cow disease -- appears to have slowed in the UK after 146 confirmed cases since the epidemic began in the mid-1990's, a new wave of cases could be waiting in the wings, according to Australian neuroscientist Prof Colin Masters. [ + ]
Bionomics beefs financial team
Adelaide-based genomics biotech Bionomics has appointed a new heavy hitter to its financial team with the signing up of ex-Faulding and ex-Mayne commercialisation expert Lee Craker as new CFO. [ + ]
Expat's big plans to improve Anglo-Aussie ties
Expatriate Australian Dr John Sime is headed back to Australia next January, with plans to improve the links between the Australian and the British biotechnology industries. [ + ]
GroPep cuts its losses to produce second-half profit
Adelaide-based GroPep has continued to shuck off the disastrous after-effects of its purchase of Biotech Australia by posting a second-half profit for 2002-03. [ + ]
Intel eyes the bio network
There are four big targets for computer companies when it comes to networked and clustered computers: energy; manufacturing, financial services – and bioinformatics, according to John Davies, general manager of eBiz channels and marketing at Intel. [ + ]
Biotech a healthy market for chips
Intel is looking hard at the emerging market of biotech devices. [ + ]